TGFB1 and Autoimmunity: Though the best way to efficiently target Itgβ8 effects in patients needs to define, the exacerbation of the cytotoxic functions of T lymphocytes selectively in the TME suggests that targeting Itgβ8pos Tregs may represent promising immunotherapy avoiding the risk of unleashing massive autoimmunity following a systemic neutralization of TGF-β effects10.